Treatment with Specified Products - FOI Response Register

FoI Number
2023-644
Subject
Treatment with Specified Products
Date Received
23/01/2024
Request and Response
  1. In the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetinib (Mektovi) for the following diseases:

A) Metastatic Melanoma

B) Colorectal Cancer

C) Any other indications

  1. In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:

A) Metastatic Melanoma

B) Adjuvant Melanoma

C) BRAF mutated Lung Cancer

The answer to all questions is ZERO